Clinical Trial Update: A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection [Phase 2, Phase 3]

View source ↗

Summary

A multi-part open-label study evaluated ABT-450/r/ABT-267 with or without ABT-333 and ribavirin in adults with genotype 1 or 4 HCV, with or without HIV coinfect…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Hepatitis C

Drugs mentioned

• ABT-333 (ABT-333)
• ABT-450/r/ABT-267
• Ribavirin (ribavirin)

Snippet

Sponsor: AbbVie | Conditions: Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2017-11-17